Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,519.12
(
0.61%
)
US TECH 100
29,229.20
(
1.84%
)
Dow Jones
50,461.68
(
-0.23%
)
Brent Oil
95.62
(
-1.41%
)
Bitcoin
75,675.09
(
-0.22%
)
News Focus
News Focus
Post# of 257644
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123024
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 116132

Tuesday, 03/08/2011 5:26:53 PM

Tuesday, March 08, 2011 5:26:53 PM

Post# of 257644
Unlike Teva (who has sought to hide the origins of its Lovenox knockoff), MYL has been candid in acknowledging that its version of Copaxone is the same drug Natco sells as a Copaxone knockoff in India.

I don’t think MYL has a serious chance of getting FDA approval, whether or not they opt to run a clinical trial.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today